PNC Financial Services Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.07M | Buy |
6,337
+707
| +13% | +$105K | ﹤0.01% | 1357 |
|
|
2026
Q1 | $742K | Buy |
5,630
+614
| +12% | +$81.5K | ﹤0.01% | 1442 |
|
|
2025
Q4 | $711K | Buy |
5,016
+248
| +5% | +$35.9K | ﹤0.01% | 1435 |
|
|
2025
Q3 | $669K | Buy |
4,768
+384
| +9% | +$52K | ﹤0.01% | 1465 |
|
|
2025
Q2 | $551K | Buy |
4,384
+992
| +29% | +$114K | ﹤0.01% | 1487 |
|
|
2025
Q1 | $375K | Sell |
3,392
-412
| -11% | -$52.2K | ﹤0.01% | 1727 |
|
|
2024
Q4 | $519K | Sell |
3,804
-224
| -6% | -$27.7K | ﹤0.01% | 1502 |
|
|
2024
Q3 | $464K | Buy |
4,028
+251
| +7% | +$34.4K | ﹤0.01% | 1592 |
|
|
2024
Q2 | $520K | Buy |
3,777
+282
| +8% | +$38.7K | ﹤0.01% | 1454 |
|
|
2024
Q1 | $482K | Buy |
3,495
+248
| +8% | +$33.9K | ﹤0.01% | 1560 |
|
|
2023
Q4 | $428K | Sell |
3,247
-401
| -11% | -$46.2K | ﹤0.01% | 1622 |
|
|
2023
Q3 | $410K | Sell |
3,648
-66
| -2% | -$6.95K | ﹤0.01% | 1613 |
|
|
2023
Q2 | $350K | Sell |
3,714
-559
| -13% | -$54.6K | ﹤0.01% | 1805 |
|
|
2023
Q1 | $433K | Buy |
4,273
+505
| +13% | +$52.5K | ﹤0.01% | 1638 |
|
|
2022
Q4 | $450K | Sell |
3,768
-19
| -0.5% | -$2.23K | ﹤0.01% | 1589 |
|
|
2022
Q3 | $403K | Buy |
3,787
+522
| +16% | +$53K | ﹤0.01% | 1649 |
|
|
2022
Q2 | $319K | Buy |
3,265
+115
| +4% | +$10.6K | ﹤0.01% | 1829 |
|
|
2022
Q1 | $296K | Buy |
3,150
+684
| +28% | +$58K | ﹤0.01% | 2017 |
|
|
2021
Q4 | $211K | Sell |
2,466
-1,037
| -30% | -$95.4K | ﹤0.01% | 2223 |
|
|
2021
Q3 | $334K | Buy |
3,503
+10
| +0.3% | +$945 | ﹤0.01% | 1878 |
|
|
2021
Q2 | $341K | Buy |
3,493
+2,861
| +453% | +$274K | ﹤0.01% | 1877 |
|
|
2021
Q1 | $62K | Sell |
632
-23
| -4% | -$2.41K | ﹤0.01% | 2856 |
|
|
2020
Q4 | $64K | Sell |
655
-117
| -15% | -$11.3K | ﹤0.01% | 2757 |
|
|
2020
Q3 | $75K | Buy |
772
+113
| +17% | +$13.1K | ﹤0.01% | 2486 |
|
|
2020
Q2 | $80K | Buy |
659
+14
| +2% | +$1.55K | ﹤0.01% | 2468 |
|
|
2020
Q1 | $55K | Sell |
645
-14
| -2% | -$1.37K | ﹤0.01% | 2572 |
|
|
2019
Q4 | $72K | Sell |
659
-49
| -7% | -$5.13K | ﹤0.01% | 2680 |
|
|
2019
Q3 | $64K | Sell |
708
-8
| -1% | -$747 | ﹤0.01% | 2770 |
|
|
2019
Q2 | $59K | Sell |
716
-309
| -30% | -$25.4K | ﹤0.01% | 2851 |
|
|
2019
Q1 | $91K | Buy |
1,025
+533
| +108% | +$44.5K | ﹤0.01% | 2606 |
|
|
2018
Q4 | $35K | Sell |
492
-43
| -8% | -$4.12K | ﹤0.01% | 3054 |
|
|
2018
Q3 | $67K | Buy |
535
+2
| +0.4% | +$227 | ﹤0.01% | 2829 |
|
|
2018
Q2 | $52K | Buy |
533
+51
| +11% | +$4.57K | ﹤0.01% | 2960 |
|
|
2018
Q1 | $39K | Buy |
482
+55
| +13% | +$4.64K | ﹤0.01% | 3107 |
|
|
2017
Q4 | $32K | Sell |
427
-1,738
| -80% | -$119K | ﹤0.01% | 3166 |
|
|
2017
Q3 | $132K | Sell |
2,165
-4,035
| -65% | -$213K | ﹤0.01% | 2372 |
|
|
2017
Q2 | $285K | Sell |
6,200
-408
| -6% | -$19.8K | ﹤0.01% | 1930 |
|
|
2017
Q1 | $286K | Sell |
6,608
-968
| -13% | -$41.5K | ﹤0.01% | 1929 |
|
|
2016
Q4 | $295K | Sell |
7,576
-13,414
| -64% | -$607K | ﹤0.01% | 1894 |
|
|
2016
Q3 | $1.06M | Sell |
20,990
-57,099
| -73% | -$2.84M | ﹤0.01% | 1244 |
|
|
2016
Q2 | $3.55M | Buy |
78,089
+6,025
| +8% | +$277K | ﹤0.01% | 735 |
|
|
2016
Q1 | $2.85M | Buy |
72,064
+14,044
| +24% | +$557K | ﹤0.01% | 796 |
|
|
2015
Q4 | $3.28M | Buy |
58,020
+8,578
| +17% | +$436K | ﹤0.01% | 726 |
|
|
2015
Q3 | $1.97M | Buy |
49,442
+18,660
| +61% | +$902K | ﹤0.01% | 946 |
|
|
2015
Q2 | $1.47M | Buy |
30,782
+21,679
| +238% | +$919K | ﹤0.01% | 1098 |
|
|
2015
Q1 | $361K | Buy |
9,103
+8,680
| +2,052% | +$310K | ﹤0.01% | 1855 |
|
|
2014
Q4 | $9K | Buy |
423
+200
| +90% | +$3.79K | ﹤0.01% | 3399 |
|
|
2014
Q3 | $3K | Hold |
223
| – | – | ﹤0.01% | 3585 |
|
|
2014
Q2 | $3K | Hold |
223
| – | – | ﹤0.01% | 3437 |
|
|
2014
Q1 | $4K | Buy |
+223
| New | +$3.81K | ﹤0.01% | 3302 |
|
Other funds holding NBIX
PNC Financial Services Group's NBIX Position: Q2 2026 in Review
PNC Financial Services Group increased its Neurocrine Biosciences (NBIX) stake by 13% in Q2 2026, buying an estimated $105K and bringing the position to 6,337 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #1357.
PNC Financial Services Group first reported a position in NBIX in Q1 2014 and has held it in 50 quarters since. The position peaked at $3.55M in Q2 2016. 388 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- PNC Financial Services Group held 6,337 shares of Neurocrine Biosciences worth $1.07M as of Q2 2026.
- PNC Financial Services Group bought 707 Neurocrine Biosciences shares in Q2 2026, an estimated $105K.
- Neurocrine Biosciences made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #1357 holding.
- PNC Financial Services Group first reported a position in Neurocrine Biosciences in Q1 2014 and has held it in 50 quarters since.
- PNC Financial Services Group's Neurocrine Biosciences position peaked at $3.55M in Q2 2016.
- 388 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.